Navigation Links
Oramed's Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the 2009 British Pharmaceutical Conference in Manchester, England
Date:8/18/2009

JERUSALEM, August 18 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTC: ORMP) (http://www.oramed.com), a developer of alternative drug delivery systems, announced today that Oramed's Chief Scientific Officer, Miriam Kidron, Ph.D. was chosen to present an overview of the clinical development of Oramed's Oral Insulin capsule at Science@BPC of the 2009 British Pharmaceutical Conference ("BPC"), in Manchester, England on September 9, 2009.

Science@BPC is an event that is the result of the collaboration between two organizations, the Royal Pharmaceutical Society of Great Britain and the Academy of Pharmaceutical Sciences. The two organizations describe the event as "The UK's premier medicines discovery and development event, showcasing excellence in the pharmaceutical sciences." The focus of the BPS this year is the innovative discovery, delivery, and diagnostic technologies aimed at fighting cancer, infectious diseases and diabetes.

Dr. Kidron will present her lecture titled: "Oral Insulin: From Bench to Humans" during the session titled: "Delivering Anti-diabetic Medicines." The lecture will begin at 2:15 pm BST (9:15 am EDT, 6:15 am PDT) on September 9, 2009. Dr. Kidron commented, "Oramed is pleased to have been invited to the BPC to share the clinical development of its Oral Insulin Capsule with the pharmaceutical community."

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://www.oramed.com.

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.

    Company and Investor Relations Contacts:
    Oramed Pharmaceuticals
    Tara Horn
    USA:    +1-646-240-4193
    Int'l:  +972-54-334-318
    Office: +972-2-566-0001
    Email: tara@oramed.com



'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
2. OxyBand Technologies, Inc. Hires a Leader in Medical Technology as Chief Technology Officer
3. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
4. Dr. Peter Nash, Ph.D. Joins Mach One Corporation as Chief Scientist
5. Molecular Biometrics Hires Denny Sakkas, PhD Renowned Yale Embryologist and International Thought-Leader, as Chief Scientific Officer; Opening U.S. Research Facility
6. Xytis Names Gordon H. Busenbark as Chief Financial Officer
7. Quark Pharmaceuticals Appoints New Chief Medical Officer
8. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
9. Great Basin Scientific, Inc. Raises $3.6 Million in Bridge Funding to Prepare for Launch of First Product
10. Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions
11. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Feb. 12, 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO ) is pleased to ... Account Management and Payor Strategies effective Jan. 23, 2016. ... ... ... Diplomat Specialty Pharmacy ...
(Date:2/12/2016)... Inc., a medical device company that pioneered the use of the ... device indicated for fusion for certain disorders of the sacroiliac (SI) ... Contractor (MAC) covering the states of Connecticut , ... Massachusetts , Minnesota , ... Rhode Island , Vermont and ...
(Date:2/12/2016)... and SEOUL, South Korea ... Menarini and Macrogen, Inc. today announced they will ... innovative procedures for precision medicine in cancer. The ... Biosystems, DEPArray™ digital-sorting technology with Macrogen,s high-throughput Next ... certified under the Clinical Laboratory Improvement Amendments (CLIA) ...
Breaking Medicine Technology:
(Date:2/13/2016)... Memphis, Tennessee (PRWEB) , ... February 13, 2016 ... ... Louise Herrington School of Nursing with an in-kind gift of a VeinViewer® Vision ... help students as they learn how to start an IV and draw blood, ...
(Date:2/13/2016)... ... 2016 , ... DDi , a Makro company, makes ... its expertise in eClinical Solutions. DDi has built its solution competency with a ... global clients. DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains ...
(Date:2/12/2016)... ... February 12, 2016 , ... The law firm of Morrow, ... Parishes. The purpose of these scholarships is to encourage applicants to pursue a ... seek employment within these two parishes. , “We have available jobs in St. ...
(Date:2/12/2016)... ... ... CDRH Enforcement Trends: , Back to the Future , Feb. 25, 2016 — 11:00 a.m. ... “Those who don’t learn from history are doomed to repeat it.” , An analysis of ... year. But that takes time. , Take a close look at the warning letters ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... As a ... hectic schedule, a demanding job, and no time to decompress, Rabinowitz found herself drawn ... herself to meditation for its impact on her life, implementing a 20-minute-per-day meditation practice ...
Breaking Medicine News(10 mins):